首页> 外文期刊>Clinical and experimental hypertension: CEH >Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension
【24h】

Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension

机译:高血压受试者人ChyMase抑制剂型多脂素水化液L的前瞻性单臂观察研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Purpose: Human chymase (h-chymase) is a serine protease that forms local angiotensin II and has been proven to be related to onset of hypertension, arteriosclerosis, and post myocardial infarction cardiac remodeling. Since no chymase inhibitor was clinically available, an extensive screening for inhibition of h-chymase in three different extracts (water, hot water,?and ethanol) of approximately 800 food ingredients had been performed and we identified Polygonum hydropiper L (Polygonum). Using a dried and powdered Polygonum, we conducted a prospective, single-arm, pilot study to investigate its safety and antihypertensive effect in subjects with normal high blood pressure to moderate hypertension.Methods: First, a single oral dose of Polygonum powder (4000爉g) was administered to assess acute toxicity. Then, a pilot study was conducted in 11 subjects using the sequence of placebo and Polygonum for 2爓eeks each. The dose of Polygonum was increased sequentially (2002000爉g/day). Home blood pressure and pulse rate were monitored.Results: Oral administration of Polygonum (4000爉g) did not cause any adverse events. In the dose-escalation phase, evening systolic blood pressure was significantly decreased at 800爉g, 2000爉g doses post-treatment (p??.05, and p??.05, respectively). Depressor responders to Polygonum intake had significantly higher salt intake in spot urine (p??.05). No adverse events or reactions occurred.Conclusion: This was the first investigation that an h-chymase inhibitory Polygonum intake for safety and tolerability was proven and, in addition, chymase inhibitory Polygonum appeared to have depressor effect especially in a hypertensive subject with excessive salt intake.
机译:背景论:人冠蛋白酶(H-ChyMase)是一种丝氨酸蛋白酶,其形成局部血管紧张素II,并已被证明与高血压,动脉硬化和后心肌梗死心脏重塑的发作有关。由于临床上没有冠血酶抑制剂,已经进行了大约800种食品成分的三种不同提取物(水,热水,α和乙醇)中的H-ChyMase的广泛筛选,并且我们鉴定了多谷氨酸水化器L(Polygonum)。使用干燥和粉末的薄饼,我们进行了一项前瞻性的单臂,试验研究,以研究其在具有正常高血压的受试者中的安全性和抗高血压效应,以中度高血压。方法:第一,单一口服剂量的薄片粉(4000° G)被施用以评估急性毒性。然后,在11个受试者中,使用安慰剂和多谷序列的11个受试者进行试验研究,每个序列为2‰EEK。依次增加多粒剂(2002000×G /天)。监测家庭血压和脉搏率。结果:口服施用【4000‰)没有造成任何不良事件。在剂量升级阶段,晚上的收缩压在800℃,2000℃剂量后处理显着降低(P ?? 05和P ??。05)。减压响应者对薄粒子摄入量显着高于现场尿液中的盐摄入量(p ??。05)。没有发生不良事件或反应。结论:这是先进的第一次研究,即证明了安全性和可耐受性的H-ChyMase抑制型助粒摄入量,此外,冠心酶抑制薄膜似乎具有减压效应,特别是在具有过量盐的高血压受试者中的压抑效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号